A Chinese research team has achieved a breakthrough with its newly developed RNA editing technology, named LEAPER, in the ...
Report covers Silexion Therapeutics (NASDAQ: SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the company’s ...
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ...
Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An ...
Zacks Small Cap Research on MSN
RNAZ: Introducing RNA therapeutics
By John Vandermosten, CFA NASDAQ: RNAZ READ THE FULL RNAZ RESEARCH NOTE RNA Oncology Ribonucleic acid (RNA) oncology is a specialized field in the cancer space that focuses on using RNA-based ...
Univeristy of Nebraska-Lincoln (UNL) scientist Ana Maria Vélez is pioneering a genetic treatment to contain western corn rootworm. The research seeks to contain agricultural pests by targeting ...
Bacteriophages, or phages for short, are viruses that infect bacteria. Using phages therapeutically could be very useful in fighting antibiotic-resistant pathogens, but the molecular interactions ...
LONDON--(BUSINESS WIRE)--Silexion Therapeutics (NASDAQ: SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results